Antibiotic Prophylaxis in Primary Immune Deficiency Disorders

Kuruvilla, Merin; Morena, M. Teresa de la

doi:10.1016/j.jaip.2013.09.013

Cited by 76 publications

(51 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…818 Prophylactic antibiotics and early culture-directed antibiotics were recommended by expert groups. 815,[819][820][821][822][823] Yet there are no consensus guidelines on the use of antibiotics in refractory CRS with immunodeficiency.…”

Section: Because Of Limited Data Crswnp and Crssnp Are Combined In Tmentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

Orlandi

Kingdom

Hwang

et al. 2016

Int Forum Allergy Rhinol

554

888

View full text Add to dashboard Cite

Background:The body of knowledge regarding rhinosinusitis (RS) continues to expand, with rapid growth in number of publications, yet substantial variability in the quality of those presentations. In an effort to both consolidate and critically appraise this information, rhinologic experts from around the world have produced the International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR:RS). Methods:Evidence-based reviews with recommendations (EBRRs) were developed for scores of topics, using previously reported methodology. Where existing evidence was insufficient for an EBRR, an evidence-based review (EBR) was produced. The sections were then synthesized and the entire manuscript was then reviewed by all authors for consensus. Results:The resulting ICAR:RS document addresses multiple topics in RS, including acute RS (ARS), chronic RS (CRS) with and without nasal polyps (CRSwNP and CRSsNP), recurrent acute RS (RARS), acute exacerbation of CRS (AE-CRS), and pediatric RS. Conclusion:As a critical review of the RS literature, ICAR:RS provides a thorough review of pathophysiology and evidence-based recommendations for medical and surgical treatment. It also demonstrates the significant gaps in our understanding of the pathophysiology and optimal management of RS. Too o en the foundation upon which these recommendations are based is comprised of lowerlevel evidence. It is our hope that this summary of the evidence in RS will point out where additional research efforts may be directed. C 2016 ARS-AAOA, LLC. Key Words:rhinosinusitis; chronic rhinosinusitis; acute rhinosinusitis; recurrent acute rhinosinusitis; evidence-based medicine; systematic review; endoscopic sinus surgery List of Abbreviations Used

show abstract

Section: Because Of Limited Data Crswnp and Crssnp Are Combined In Tmentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

Orlandi

Kingdom

Hwang

et al. 2016

Int Forum Allergy Rhinol

554

888

View full text Add to dashboard Cite

show abstract

“…16,[25][26][27][28] Ragab et al 15 compared erythromycin with surgery in 90 patients with CRS and found that both treatments elicited similar improvements in symptom scores and endoscopic findings at follow-up. They suggested that CRS should be treated initially with aggressive medical treatment before a decision is made regarding surgical intervention.…”

Section: Discussionmentioning

confidence: 99%

Recurrent Acute Rhinosinusitis Prevention by Azithromycin in Children with Nonallergic Rhinitis

Veskitkul

Wongkaewpothong

Thaweethamchareon

et al. 2017

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

“…The direct comparison of complement immunodeficiencies in this study highlights the differences in clinical phenotypes, with Pneumococcal disease being the predominant problem in classical pathway defect, indicating the importance of ensuring up to date Pneumococcal vaccination in this subgroup. In contrast, meningococcal disease is less of a problem in classical pathway defects but more common in patients with terminal component defects, emphasising that it is this group where quadrivalent (ACW135Y) conjugate vaccine [37] and group B vaccine [38] as well as supplementary prophylactic antibiotics should be prioritized [39]. The recognition that defects in complement underlie a number of auto-inflammatory diseases leading to acute, or chronic renal failure that can potentially have a poor outcome, even after kidney transplantation highlight the need for physicians to accurately diagnose and develop biologic and stem cell therapies that address the primary pathogenesis if patients are to be treated successfully [40].…”

Section: Discussionmentioning

confidence: 99%